Premium
The outcomes of an impaired powerhouse in KRAS mutant lung adenocarcinoma cells by Elesclomol
Author(s) -
Albayrak Gulsah,
Korkmaz Funda Demirtas,
Tozcu Duygu,
Dogan Turacli Irem
Publication year - 2019
Publication title -
journal of cellular biochemistry
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.028
H-Index - 165
eISSN - 1097-4644
pISSN - 0730-2312
DOI - 10.1002/jcb.28342
Subject(s) - protein kinase b , cancer research , kras , apoptosis , mapk/erk pathway , viability assay , biology , chemistry , cancer , medicine , signal transduction , microbiology and biotechnology , biochemistry , colorectal cancer
Objectives Lung cancer stands out as the most common cancer type worldwide. The most common genetic alteration detected in adenocarcinoma patients is KRAS. KRAS mutated patients still cannot get benefit from precision medicine approaches and lack a targeted therapy. Elesclomol is an investigational agent for melanoma and other malignancies. In this study, we evaluated its effect on cellular apoptosis, survival, and metastasis mechanisms on KRAS mutant A549 and Calu‐1 cell lines. Methods The cytotoxic effects of Elesclomol on A549 and Calu‐1 cells were determined by 3‐(4,5‐dimethylthiazol‐2‐yl)‐2,5‐diphenyltetrazolium bromide (MTT) cell viability test. Cells were treated with IC 50 concentration and then apoptosis‐related (Casp‐3, Casp‐9, Bcl‐2, and Bcl‐xL), survival‐related (Akt, p‐Akt, Erk, and p‐Erk), and metastasis‐related (E‐cadherin, Vimentin, MMP‐2, and MMP‐9) protein expressions were determined by Western blot analysis. Elesclomol's effect on cell migration was evaluated by wound healing. Total oxidant, malondialdehyde (MDA), and glutathione (GSH) levels after Elesclomol treatment were assessed. Results Elesclomol not only induced apoptotic proteins but also inhibited metastatic protein expressions and migration in both cells. Also, p‐Erk activity was diminished by Elesclomol treatment as a reflection of decreased proliferation. However, p‐Akt was enhanced as a cellular survival mechanism. Although Elesclomol's effects on oxidative stress parameters were puzzling, it induced total oxidant status (TOS), and MDA in Calu‐1 cells. Conclusion Elesclomol might provide an alternative treatment approach for patients with KRAS mutant lung adenocarcinoma and other solid tumor malignancies that harbor KRAS mutations. This would enable the development of biomarker‐driven targeted therapy for KRAS mutant adenocarcinoma patients.